SMMT Key Statistics, Chart & Performance
The current stock price of SMMT is 17.98 USD. In the past month the price increased by 2.45%. In the past year, price increased by 4.46%.
SMMT Latest News, Press Relases and Analysis
SMMT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.65 | 394.99B | ||
| AMGN | AMGEN INC | 14.53 | 171.16B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 149.90B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.34 | 111.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.89B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 833.47 | 56.16B | ||
| INSM | INSMED INC | N/A | 41.81B | ||
| NTRA | NATERA INC | N/A | 33.05B | ||
| BIIB | BIOGEN INC | 10.7 | 26.28B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B | ||
| INCY | INCYTE CORP | 15.14 | 19.08B |
Related stock screener links
About SMMT
Company Profile
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 159 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Company Info
SUMMIT THERAPEUTICS INC
601 Brickell Key Drive, Suite 1000
Miami FLORIDA 02142 US
CEO: Robert W. Duggan
Employees: 159
Phone: 13052032034
SUMMIT THERAPEUTICS INC / SMMT FAQ
Can you describe the business of SUMMIT THERAPEUTICS INC?
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 159 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
What is the stock price of SUMMIT THERAPEUTICS INC today?
The current stock price of SMMT is 17.98 USD. The price decreased by -3.49% in the last trading session.
Does SMMT stock pay dividends?
SMMT does not pay a dividend.
How is the ChartMill rating for SUMMIT THERAPEUTICS INC?
SMMT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of SMMT stock?
SUMMIT THERAPEUTICS INC (SMMT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for SUMMIT THERAPEUTICS INC?
SUMMIT THERAPEUTICS INC (SMMT) currently has 159 employees.
What is the outstanding short interest for SUMMIT THERAPEUTICS INC?
The outstanding short interest for SUMMIT THERAPEUTICS INC (SMMT) is 30.09% of its float.
SMMT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SMMT. When comparing the yearly performance of all stocks, SMMT turns out to be only a medium performer in the overall market: it outperformed 53.05% of all stocks.
SMMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SMMT. While SMMT has a great health rating, there are worries on its profitability.
SMMT Financial Highlights
Over the last trailing twelve months SMMT reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -122.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.81% | ||
| ROE | -56.93% | ||
| Debt/Equity | 0 |
SMMT Forecast & Estimates
23 analysts have analysed SMMT and the average price target is 32.93 USD. This implies a price increase of 83.16% is expected in the next year compared to the current price of 17.98.